Peter Lindquist
Overview
Explore the profile of Peter Lindquist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
25
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gasbjerg L, Rasmussen R, Dragan A, Lindquist P, Melchiorsen J, Stepniewski T, et al.
Br J Pharmacol
. 2024 Jul;
PMID: 38952084
Background And Purpose: The gut hormone glucose-dependent insulinotropic polypeptide (GIP) signals via the GIP receptor (GIPR), resulting in postprandial potentiation of glucose-stimulated insulin secretion. The translation of results from rodent...
2.
Kizilkaya H, Sorensen K, Madsen J, Lindquist P, Douros J, Bork-Jensen J, et al.
Nat Metab
. 2024 Jun;
6(7):1268-1281.
PMID: 38871982
Incretin-based therapies are highly successful in combatting obesity and type 2 diabetes. Yet both activation and inhibition of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) in combination with glucagon-like peptide-1...
3.
Larsen C, Lindquist P, Rosenkilde M, Madsen A, Haselmann K, Glendorf T, et al.
Chembiochem
. 2024 May;
25(13):e202400201.
PMID: 38701360
Selective modification of peptides is often exploited to improve pharmaceutically relevant properties of bioactive peptides like stability, circulation time, and potency. In Nature, natural products belonging to the class of...
4.
Rosenkilde M, Lindquist P, Kizilkaya H, Gasbjerg L
Peptides
. 2024 Apr;
177:171212.
PMID: 38608836
Surprisingly, agonists, as well as antagonists of the glucose-dependent insulinotropic polypeptide receptor (GIPR), are currently being used or investigated as treatment options for type 2 diabetes and obesity - and...
5.
Lindquist P, Gasbjerg L, Mokrosinski J, Holst J, Hauser A, Rosenkilde M
Front Endocrinol (Lausanne)
. 2022 Jul;
13:891586.
PMID: 35846282
The intestinal hormone, glucose-dependent insulinotropic polypeptide (GIP), is involved in important physiological functions, including postprandial blood glucose homeostasis, bone remodeling, and lipid metabolism. While mutations leading to physiological changes can...
6.
Gabe M, Gasbjerg L, Gadgaard S, Lindquist P, Holst J, Rosenkilde M
Br J Pharmacol
. 2022 May;
179(18):4473-4485.
PMID: 35523760
Background And Purpose: To fully elucidate the regulatory role of the GLP-2 system in the gut and the bones, potent and selective GLP-2 receptor (GLP-2R) antagonists are needed. Searching for...
7.
van der Velden W, Lindquist P, Madsen J, Stassen R, Wewer Albrechtsen N, Holst J, et al.
J Biol Chem
. 2021 Nov;
298(2):101413.
PMID: 34801547
Naturally occurring missense variants of G protein-coupled receptors with loss of function have been linked to metabolic disease in case studies and in animal experiments. The glucagon receptor, one such...
8.
Lindquist P, Madsen J, Brauner-Osborne H, Rosenkilde M, Hauser A
Front Endocrinol (Lausanne)
. 2021 Jul;
12:698511.
PMID: 34220721
Strong efforts have been placed on understanding the physiological roles and therapeutic potential of the proglucagon peptide hormones including glucagon, GLP-1 and GLP-2. However, little is known about the extent...